Ronnie Yeager
Research Fellow - Emerging Therapeutic Platforms & Development Sciences Abbvie
Dr. Ronnie Yeager, PhD, DABT, is currently a Research Fellow in Emerging Therapeutic Platforms at AbbVie and a board-certified toxicologist with over 15 years of drug development experience with small and large molecule programs across multiple therapeutic areas. He is the lead for the matrixed Development Sciences ADC platform team of 10+ cross-functional members, to develop and execute the research strategy in alignment with discovery partners. He has supported compound advancement to FIH trials and regulatory filings/interactions (US and ex-US), including breakthrough therapy/accelerated approval pathways, through mid-late-stage clinical development. He is also the Preclinical Safety lead for Emrelis™ (telisotuzumab-vedotin); AbbVie’s first FDA approval of an internally developed ADC solid tumor asset (lung cancer).
Seminars
- How pharma teams are collaborating within IQ MPS Affiliate to progress simple and complex in vitro NAM platforms toward regulatory acceptance
- Review insights from recent FDA publication on submitted NAM case examples and reviewer feedback – what works and what can be improved (need for well-articulated context-of-use)
- Discuss the value of a strong regulatory strategy: Suggestions for the qualification of alternative approaches leveraging toxicology data, statistical modelling, and AI – based on VICT3R experience
- Gain practical guidance for integrating in vitro and in silico NAMs into toxicology packages without over-claiming translatability
- What industry needs from consortia, regulators, and data-sharing frameworks to accelerate adoption of novel platforms covering diverse mechanisms of injury
- Leveraging complex in vitro models to evaluate ADC-induced lung toxicity
- Building in vitro tools for high-throughput compound screening
- Pending relevance to pathogenesis of ILD, high-throughput imaging-based assays may potentially be incorporated into a holistic screening approach to differentiate ADCs and guide selection of safer compounds
